Skip to main content
SLDB
NASDAQ Life Sciences

Perceptive Advisors Invests $49.9M in Solid Biosciences Private Placement, Boosting Stake to 12.9%

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$8.157
Mkt Cap
$601.078M
52W Low
$2.41
52W High
$8.72
Market data snapshot near publication time

summarizeSummary

Perceptive Advisors disclosed a $49.9 million investment in Solid Biosciences' recent private placement, acquiring pre-funded warrants and increasing its beneficial ownership to 12.9%.


check_boxKey Events

  • Major Investment in Private Placement

    Perceptive Advisors, through its Master Fund, acquired 8,912,655 pre-funded warrants for $49.9 million in Solid Biosciences' private placement, which closed on March 9, 2026.

  • Increased Beneficial Ownership

    This investment increases Perceptive Advisors' beneficial ownership in Solid Biosciences to 12.9% of the outstanding common stock.

  • Warrant Exercise Limitation

    The pre-funded warrants include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99%.

  • Follows Previously Announced Capital Raise

    This disclosure details a significant participant in the $240 million private placement announced by Solid Biosciences on March 6, 2026, and follows other investor disclosures related to the same event.


auto_awesomeAnalysis

This Schedule 13D/A filing reveals Perceptive Advisors' substantial participation in Solid Biosciences' recently announced $240 million private placement. The $49.9 million investment, through the acquisition of pre-funded warrants, significantly increases Perceptive's beneficial ownership to 12.9%. While the warrants have a 9.99% exercise limitation, this large investment by a prominent life sciences investor signals strong institutional confidence in Solid Biosciences, especially following the positive clinical data reported on March 11, 2026. This capital infusion, detailed by a major investor, strengthens the company's financial position and extends its cash runway.

At the time of this filing, SLDB was trading at $8.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $601.1M. The 52-week trading range was $2.41 to $8.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SLDB - Latest Insights

SLDB
Apr 10, 2026, 4:10 PM EDT
Filing Type: PRE 14A
Importance Score:
8
SLDB
Mar 19, 2026, 5:04 PM EDT
Filing Type: S-3
Importance Score:
7
SLDB
Mar 19, 2026, 5:03 PM EDT
Filing Type: S-3
Importance Score:
7
SLDB
Mar 19, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
SLDB
Mar 17, 2026, 6:50 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
SLDB
Mar 11, 2026, 5:34 PM EDT
Filing Type: 8-K
Importance Score:
9
SLDB
Mar 11, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
SLDB
Mar 11, 2026, 1:02 PM EDT
Source: Reuters
Importance Score:
9
SLDB
Mar 10, 2026, 5:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
SLDB
Mar 10, 2026, 4:38 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8